Alphyn Closes USD 25 Million Oversubscribed Series B Financing Round to Advance Dermatology Pipeline
Alphyn has closed an oversubscribed USD 25 million Series B financing round to support its dermatology pipeline, including a global Phase II (b) trial in atopic dermatitis and a Phase II clinical programme in molluscum contagiosum.
Angel Physicians Fund | 16/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy